Quetmolimab

奎莫利单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameQuetmolimab
Drug Alias NameQuetmolimab - EA PharmaE-6011KANAB-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionC-X3-C motif chemokine ligand 1 antagonists
TargetsC-X3-C motif chemokine ligand 1
Therapy Area/IndicationsCrohn DiseaseCholangitis, SclerosingArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaPolandRussian Federation +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEa Pharma Co Ltd
Inactive CompaniesEisai IncEisai Co Ltd
Active IndicationsCrohn Disease
Inactive IndicationsCholangitis, SclerosingArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A